drugset / Trial / NCT07074457
Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of chidamide combined with brentuximab vedotin regimen for CD30 positive PTCL patients who are unfit for chemotherapy.
Timeline
- Start
- 2024-11-01
- Primary completion
- 2028-08-01
- Completion
- 2028-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | Intravenous |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |